JP2018509908A5 - - Google Patents

Info

Publication number

JP2018509908A5

JP2018509908A5 JP2017548953A JP2017548953A JP2018509908A5 JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5 JP 2017548953 A JP2017548953 A JP 2017548953A JP 2017548953 A JP2017548953 A JP 2017548953A JP 2018509908 A5 JP2018509908 A5 JP 2018509908A5

Authority

JP

Japan

Prior art keywords

antibody

drug

host cell

seq

following formula

Prior art date

2016-03-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004027 cell Anatomy 0.000 claims description 32
• 150000001875 compounds Chemical class 0.000 claims description 30
• 150000003839 salts Chemical class 0.000 claims description 26
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 22
• 229910052739 hydrogen Inorganic materials 0.000 claims description 18
• 239000001257 hydrogen Substances 0.000 claims description 18
• 125000006239 protecting group Chemical group 0.000 claims description 18
• 239000000611 antibody drug conjugate Substances 0.000 claims description 17
• 229940049595 antibody-drug conjugate Drugs 0.000 claims description 17
• 239000002202 Polyethylene glycol Substances 0.000 claims description 16
• 125000003827 glycol group Chemical group 0.000 claims description 16
• 102000039446 nucleic acids Human genes 0.000 claims description 16
• 108020004707 nucleic acids Proteins 0.000 claims description 16
• 150000007523 nucleic acids Chemical class 0.000 claims description 16
• 229920001223 polyethylene glycol Polymers 0.000 claims description 16
• 229940125644 antibody drug Drugs 0.000 claims description 15
• 239000000203 mixture Substances 0.000 claims description 13
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 12
• 229940079593 drug Drugs 0.000 claims description 12
• 239000003814 drug Substances 0.000 claims description 12
• 102000046585 human CD48 Human genes 0.000 claims description 12
• 102100036008 CD48 antigen Human genes 0.000 claims description 10
• 125000000524 functional group Chemical group 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 8
• 239000000562 conjugate Substances 0.000 claims description 8
• 229940127089 cytotoxic agent Drugs 0.000 claims description 8
• 239000002254 cytotoxic agent Substances 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 238000012258 culturing Methods 0.000 claims description 7
• 238000000034 method Methods 0.000 claims description 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
• 230000001268 conjugating effect Effects 0.000 claims description 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
• 208000034578 Multiple myelomas Diseases 0.000 claims description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
• 230000036210 malignancy Effects 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9